Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $4,276,577.98 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 142,886 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the sale, the chief financial officer now owns 112,186 shares of the company’s stock, valued at $3,357,726.98. The trade was a 56.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total value of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.79, for a total transaction of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40.

Hims & Hers Health Trading Down 7.3 %

Shares of HIMS stock opened at $19.32 on Friday. The firm’s fifty day moving average price is $19.76 and its two-hundred day moving average price is $18.87. Hims & Hers Health, Inc. has a 1 year low of $7.40 and a 1 year high of $30.44. The firm has a market capitalization of $4.15 billion, a P/E ratio of 43.91 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the previous year, the business earned ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. TD Cowen lifted their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the stock from $32.00 to $18.00 in a research report on Thursday. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Piper Sandler restated a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $20.71.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after purchasing an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC increased its position in Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the last quarter. Wellington Management Group LLP raised its stake in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after buying an additional 883,230 shares during the period. M&G Plc acquired a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $8,232,000. Finally, Geode Capital Management LLC boosted its stake in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares during the period. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.